Background: Clinical remission is an important therapeutic goal in pediatric Crohn’s disease; however, symptom resolution may not reflect complete control of intestinal inflammation. We report a child with sustained clinical remission but markedly elevated fecal calprotectin, highlighting the limitations of symptom-based monitoring.
Case Presentation Summary: A 6-year-8-month-old girl presented with recurrent bloody diarrhea, abdominal pain, weight loss, recurrent stomatitis, and severe anemia (hemoglobin 4 g/dL) requiring transfusion. Oral ulcers and an anal skin tag were noted, and fecal calprotectin was 1,159.5 µg/g. Clinical, endoscopic, histopathological, and upper gastrointestinal findings supported Crohn’s disease. She received corticosteroid induction followed by 5-aminosalicylate maintenance therapy.
Over five years of follow-up, she experienced two flares before achieving sustained clinical remission. In December 2024, she was asymptomatic with a Pediatric Crohn’s Disease Activity Index (PCDAI) <10, while colonoscopy showed minimal endoscopic activity (SES-CD 2). Maintenance sulfasalazine was interrupted in March 2026 because of medication unavailability. She remained clinically well without abdominal pain, diarrhea, or hematochezia; however, fecal calprotectin subsequently increased to >2,100 µg/g, exceeding the level at diagnosis and raising concern for persistent intestinal inflammation despite apparent clinical remission. Sulfasalazine was restarted and endoscopic reassessment was planned. Nutritional status remained satisfactory, although linear growth showed a tendency toward deceleration.
Learning Points Discussion: This case illustrates clinically important discordance between symptomatic and objective disease activity in pediatric Crohn’s disease. Absence of symptoms and PCDAI-defined remission should not be equated with biological disease control. Objective biomarkers should complement clinical assessment during remission, and discordant findings should prompt reassessment rather than reassurance based on symptoms alone. In children, this approach is particularly important because persistent subclinical inflammation may compromise growth and development. Long-term management should therefore integrate objective inflammatory monitoring with growth, nutrition, puberty, treatment adherence, and psychosocial well-being.

